四环生物(000518) - 2025 Q2 - 季度业绩预告

Jiangsu Sihuan Bioengineering Co., Ltd. 2025 Semi-Annual Performance Forecast Current Period Performance Forecast The company forecasts H1 2025 operating revenue between 180 million and 190 million yuan, a 70.12% to 79.57% increase, but expects a net loss attributable to shareholders ranging from 9 million to 13 million yuan Performance Forecast for H1 2025 | Item | Current Reporting Period (Jan 1 - Jun 30, 2025) | Prior Period | | :--- | :--- | :--- | | Operating Revenue | 180 million yuan to 190 million yuan | 105.8084 million yuan | | | Year-on-year growth: 70.12% to 79.57% | | | Net Profit Attributable to Shareholders of Listed Company | Loss: -13 million yuan to -9 million yuan | -11.0581 million yuan | | | Year-on-year change: -17.56% to 18.61% | | | Net Profit After Deducting Non-Recurring Gains and Losses | Loss: -14 million yuan to -10 million yuan | -9.8074 million yuan | | | Year-on-year decrease: -42.75% to -1.96% | | | Basic Earnings Per Share | -0.0126 yuan/share to -0.0087 yuan/share | -0.0107 yuan/share | Pre-Audit Status of Performance Forecast This performance forecast has not been audited by a certified public accountant, and its accuracy awaits final audit confirmation - This performance forecast has not been audited by a certified public accountant[2] Analysis of Performance Changes During the reporting period, the company experienced revenue growth without profit increase, primarily due to subsidiary's nursery stock sales and increased losses from the core pharmaceutical subsidiary, compounded by rising management fees from litigation expenses - Significant growth in operating revenue is primarily due to a strategic cooperation agreement between wholly-owned subsidiary Jiangsu Chenwei Ecological Park Technology Co., Ltd. and Jiangyin Xingangfa Trading Co., Ltd. for bulk sales of nursery stock[3] - The main reasons for the performance loss are a decrease in main business revenue and increased losses from the controlling subsidiary Beijing Sihuan Bio-Pharmaceutical Co., Ltd., and increased management expenses and losses for the parent company due to legal fees for securities false representation lawsuits[3] Other Relevant Information and Risk Warning The company states that this performance forecast is a preliminary estimate, with final accurate financial data subject to the 2025 semi-annual report, advising investors of potential investment risks - This performance forecast data is a preliminary estimate by the company's finance department, with specific data subject to the company's 2025 semi-annual report, reminding investors to be aware of investment risks[4][5]